Ivonescimab Plus Chemotherapy in Patients With <i>EGFR</i> Variant Non–Small Cell Lung Cancer

To the Editor We are writing to express some concerns about the methodology and interpretation of a recent study by Feng et al about treatment of pretreated epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC).1

Authors

Institutions

Publication Details

Journal
JAMA
Published
2024-12-11
DOI
https://doi.org/10.1001/jama.2024.23088
Citations
2
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non–Small Cell Lung Cancer

Guosheng Wang, Qi Mei, Wen-Chien Cheng
2 citations
JAMA
Lung Cancer Treatments and Mutations
0.84
article

Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non–Small Cell Lung Cancer

Guosheng Wang, Qi Mei, Wen-Chien Cheng
article en
2 citations

Abstract

To the Editor We are writing to express some concerns about the methodology and interpretation of a recent study by Feng et al about treatment of pretreated epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC).1

JAMAVol. 333(2)
Shanxi Medical University (CN), China Medical University (TW), China Medical University Hospital (TW), Shanghai East Hospital (CN), Shanxi Academy of Medical Sciences (CN)
Zero hunger
Openalex Percentile: Top 22%
Lung Cancer Treatments and Mutations
0.84
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.